tetano
Editor, Senior Moderator
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790. doi: 10.1016/j.csbj.2020.03.025. eCollection 2020.
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
Beck BR[SUP]1[/SUP], Shin B[SUP]1,[/SUP][SUP]2[/SUP], Choi Y[SUP]1[/SUP], Park S[SUP]1[/SUP], Kang K[SUP]3[/SUP].
Author information
Abstract
The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with K[SUB]d[/SUB] of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with K[SUB]d[/SUB] < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.
? 2020 The Authors.
KEYWORDS:
Atazanavir; COVID-19; Coronavirus; Deep learning; Drug repurposing; MT-DTI; SARS-CoV-2
PMID:32280433PMCID:PMC7132116DOI:10.1016/j.csbj.2020.03.025
Free full text
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
Beck BR[SUP]1[/SUP], Shin B[SUP]1,[/SUP][SUP]2[/SUP], Choi Y[SUP]1[/SUP], Park S[SUP]1[/SUP], Kang K[SUP]3[/SUP].
Author information
Abstract
The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with K[SUB]d[/SUB] of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with K[SUB]d[/SUB] < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.
? 2020 The Authors.
KEYWORDS:
Atazanavir; COVID-19; Coronavirus; Deep learning; Drug repurposing; MT-DTI; SARS-CoV-2
PMID:32280433PMCID:PMC7132116DOI:10.1016/j.csbj.2020.03.025
Free full text